



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Corrigendum

Corrigendum to “A novel screening model for the molecular drug for diabetes and obesity based on tyrosine phosphatase Shp2” [Bioorg. Med. Chem. Lett. 21 (2011) 874]

Yanyan Bu^{a,†}, Tao Shi^{b,†}, Minghui Meng^{a,†}, Guiping Kong^a, Yingpu Tian^a, Quancheng Chen^b,
Xinsheng Yao^{b,c}, Gensheng Feng^{a,d}, Haifeng Chen^{b,*}, Zhongxian Lu^{a,*}

^a Xiamen City Key Laboratory of Metabolism Disease and Metabolic Disease Research Center, Institute for Biomedical Research, Lu Jiaxi Hall, Room 630, Xiamen University, Xiamen, Fujian 361005, China

^b Nature Product Research Center, Institute for Biomedical Research, Xiamen University, Xiamen, Fujian 361005, China

^c Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, China

^d Molecular Pathology Graduate Program, University of California San Diego, La Jolla, CA 92093, USA

The name of Haifeng Chen mistakenly appeared as Haifeng Cheng in the author line. The correct author line appears above.

DOI of original article: [10.1016/j.bmcl.2010.11.049](https://doi.org/10.1016/j.bmcl.2010.11.049)

* Corresponding author. Tel./fax: +86 592 2187227.

E-mail addresses: haifeng@xmu.edu.cn (H. Chen), zhongxian@xmu.edu.cn (Z. Lu).

[†] These authors have equal contribution.